Related Experiment Video
Updated: Oct 21, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Therapeutic plasma exchange for life-threatening pediatric disorders
Jean-Sebastien Diana1,2, Sandra Manceau1,2, Tioka Rabeony3
1Hôpital Necker Enfants Malades, Paris, France.
Insights
Therapeutic plasma exchange (TPE) is a viable treatment for critically ill children, with most adverse events being mild and unrelated to treatment specifics. This study confirms TPE
Area of Science:
- Pediatric Nephrology
- Pediatric Hematology
- Critical Care Medicine
Background:
- Therapeutic plasma exchange (TPE) is recognized for treating severe pediatric disorders.
- Research on apheresis in pediatric populations is limited, with few studies featuring adequate patient numbers or control groups.
- This study aimed to assess the safety and tolerance of TPE in pediatric patients.
Purpose of the Study:
- To evaluate the tolerance and safety of therapeutic plasma exchange (TPE) in a pediatric cohort.
- To identify potential risk factors associated with adverse events during TPE in children.
- To contribute to the limited body of evidence on pediatric apheresis.
Main Methods:
- Retrospective cohort study analyzing data from pediatric patients who underwent TPE between January 2005 and December 2014.
- Data collected via a web-based electronic case report form.
- Analysis included patient demographics, TPE indications, procedure details, and adverse events.
Main Results:
- 78 pediatric patients underwent 731 TPE procedures for various conditions, including antibody-mediated rejection, thrombotic microangiopathy, and inflammatory diseases.
- The majority of patients (92%) experienced adverse events (AEs), but most were mild and not linked to specific treatment parameters.
- No deaths were attributed to the TPE procedure itself.
Conclusions:
- This study represents one of the largest retrospective analyses of TPE in children to date.
- TPE is feasible and can be safely administered to pediatric patients with life-threatening and refractory conditions.
- The findings support the use of TPE in specialized pediatric care settings.
Introduction:
Therapeutic plasma exchange (TPE) is acknowledged to be an effective treatment in life-threatening pediatric disorders. Apheresis for pediatric diseases has been poorly investigated, and most studies to date featured small numbers of patients and lacked control groups. The objective of the present study was to evaluate the tolerance of TPE in pediatric patients.
Materials And Methods:
A retrospective cohort study via a web-based electronic case report form including pediatric patients referred for TPE between January 2005 and December 2014.
Results:
A total of 78 patients (median [range] age: 9.8 [0.53-17.93]) and 731 TPE procedures were analyzed. The indications were antibody-mediated rejection (n = 33; 42%) and desensitization therapy (n = 5; 6%) after solid organ or hematopoietic stem cell transplantation, thrombotic microangiopathy (n = 17; 22%), pediatric inflammatory diseases (n = 16; 21%), kidney diseases (n = 6; 8%), and hyperviscosity syndrome (n = 1; 1%). On average, each patient underwent six procedures during the first session [range: 1-19]. In the 2 weeks following the start of a session, 72 patients (92%) presented a total of 311 adverse events (AEs) potentially related to TPE. The risk of AEs was not related to the indication for TPE, the intensity of care, venous access, plasma substitute use, or body weight. None of the deaths was related to the TPE.
Conclusion:
We studied one of the largest retrospective pediatric cohorts described to date. Our experience of TPE children's TPE feasibility concerned specific, life-threatening conditions and otherwise treatment-refractory diseases.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Pharmacokinetics in Pediatric Patients: Drug Distribution
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Acute Kidney Injury V: Interprofessional Care
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

